Agios Pharmaceuticals Inc (AGIO) 48.63 $AGIO
Jim Cramer's Top Stock Picks: AGIO AAPL LUV
at The Street - Wed Sep 17, 5:00AM CDT
Cramer says the charts predict a rally soon for Apple stock while Southwest remains his favorite airline.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Agios Pharmaceuticals (AGIO): Today's Weak On High Volume Stock
at The Street - Fri Sep 12, 9:08AM CDT
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate
Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for the treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is a first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies.
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Tue Aug 12, 12:38PM CDT
Levi & Korsinsky, LLP is investigating Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 6:30AM CDT
- AG-221: Company on track to start four Phase 1 expansion cohorts in second half of 2014; abstract of additional Phase 1 data submitted to the 2014 ASH Annual Meeting -
Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Mon Jul 28, 8:00AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that it will host a conference call and live webcast on Thursday, August 7, 2014 at 8:30 a.m. EDT to report its second quarter 2014 financial results and discuss recent business activities.
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
Orphan Drug Designations, Financial Results, Board Elections, and Raised Financial Guidance - Analyst Notes on Agios, Alder, Healthways, NeoGenomics and Sequenom
PR Newswire - Wed Jul 02, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Healthways Inc. (NASDAQ: HWAY), NeoGenomics Inc. (NASDAQ: NEO) and Sequenom Inc. (NASDAQ: SQNM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4351-100free.
5 Stocks With Big Insider Buying
at The Street - Wed Jun 25, 11:53AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
Nasdaq stocks posting largest percentage decreases
AP - Tue Jun 24, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Agios Presents Data on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 4:21PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced new clinical data from the ongoing phase I study on candidate, AG-221, among patients suffering from IDH2 mutant positive hematologic malignancies.
2 Surging Biotechs with Links to Celgene
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 16, 1:03PM CDT
Celgene is sharing its experience and opening its wallet to a slate of fledgling biotech companies in a bid to lock-up the next generation of game-changing therapies. Agios and bluebird bio are two of those companies and each reported news...
Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia
Business Wire - Mon Jun 16, 7:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia (AML). AG-221 is an oral, first-in-class IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
3 Stocks Rising on Unusual Volume
at The Street - Mon Jun 16, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies
Business Wire - Sat Jun 14, 6:31AM CDT
--Agios Pharmaceuticals to Host Investor Webcast on June 16, 2014 at 8:30 a.m. EDT
Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration
Business Wire - Fri Jun 13, 7:03AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that its partner Celgene Corporation has exercised its option to an exclusive worldwide license to AG-221, an oral, first-in-class, potent inhibitor of the mutant IDH2 protein. Under the terms of the agreement, the option to license extended to Celgene through the end of Phase 1, but AG-221 has been exercised early based on the Phase 1 data generated to date. AG-221 is currently in a Phase 1 dose escalation study in patients that harbor an IDH2 mutation with advanced hematologic malignancies, including acute myeloid leukemia (AML).
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
Jim Cramer's Top Stock Picks: AGIO AAPL LUV
at The Street - Wed Sep 17, 5:00AM CDT
Cramer says the charts predict a rally soon for Apple stock while Southwest remains his favorite airline.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Agios Pharmaceuticals (AGIO): Today's Weak On High Volume Stock
at The Street - Fri Sep 12, 9:08AM CDT
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate
Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for the treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is a first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies.
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Agios Pharmaceuticals, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Tue Aug 12, 12:38PM CDT
Levi & Korsinsky, LLP is investigating Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
Agios Pharmaceuticals Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 6:30AM CDT
- AG-221: Company on track to start four Phase 1 expansion cohorts in second half of 2014; abstract of additional Phase 1 data submitted to the 2014 ASH Annual Meeting -
Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Mon Jul 28, 8:00AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that it will host a conference call and live webcast on Thursday, August 7, 2014 at 8:30 a.m. EDT to report its second quarter 2014 financial results and discuss recent business activities.
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
Orphan Drug Designations, Financial Results, Board Elections, and Raised Financial Guidance - Analyst Notes on Agios, Alder, Healthways, NeoGenomics and Sequenom
PR Newswire - Wed Jul 02, 5:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Healthways Inc. (NASDAQ: HWAY), NeoGenomics Inc. (NASDAQ: NEO) and Sequenom Inc. (NASDAQ: SQNM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4351-100free.
5 Stocks With Big Insider Buying
at The Street - Wed Jun 25, 11:53AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
Nasdaq stocks posting largest percentage decreases
AP - Tue Jun 24, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Agios Presents Data on AG-221 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 4:21PM CDT
Agios Pharmaceuticals, Inc. (AGIO) announced new clinical data from the ongoing phase I study on candidate, AG-221, among patients suffering from IDH2 mutant positive hematologic malignancies.
2 Surging Biotechs with Links to Celgene
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 16, 1:03PM CDT
Celgene is sharing its experience and opening its wallet to a slate of fledgling biotech companies in a bid to lock-up the next generation of game-changing therapies. Agios and bluebird bio are two of those companies and each reported news...
Agios Pharmaceuticals Announces Orphan Drug Designation of AG-221 for Treatment of Acute Myelogenous Leukemia
Business Wire - Mon Jun 16, 7:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia (AML). AG-221 is an oral, first-in-class IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
3 Stocks Rising on Unusual Volume
at The Street - Mon Jun 16, 5:00AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
New Agios Clinical Data from Ongoing Phase 1 Trial of AG-221 Continue to Show Complete and Durable Remissions in Patients with Difficult to Treat Hematologic Malignancies
Business Wire - Sat Jun 14, 6:31AM CDT
--Agios Pharmaceuticals to Host Investor Webcast on June 16, 2014 at 8:30 a.m. EDT
Agios Pharmaceuticals Announces that Celgene Exercised its Option to License AG-221 Under Global Strategic Collaboration
Business Wire - Fri Jun 13, 7:03AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that its partner Celgene Corporation has exercised its option to an exclusive worldwide license to AG-221, an oral, first-in-class, potent inhibitor of the mutant IDH2 protein. Under the terms of the agreement, the option to license extended to Celgene through the end of Phase 1, but AG-221 has been exercised early based on the Phase 1 data generated to date. AG-221 is currently in a Phase 1 dose escalation study in patients that harbor an IDH2 mutation with advanced hematologic malignancies, including acute myeloid leukemia (AML).
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
